Core Insights - The average return of actively managed equity funds has significantly improved, reaching 15.1% year-to-date as of August 6, with over 500 funds hitting historical net asset value highs [1][2] - There is a stark performance disparity among funds, with top performers achieving returns close to 130% while laggards have seen declines exceeding 18% [1][3] - The strong performance of leading funds is attributed to successful investments in sectors such as innovative pharmaceuticals, technology, and new consumer trends [2][3] Performance Summary - As of August 6, 127 actively managed equity funds have returns exceeding 50%, with 23 funds surpassing 80%, and 6 funds doubling their net asset value this year [2] - Specific funds like Changcheng Pharmaceutical Industry Select Mixed Fund and Bank of China Hong Kong Stock Connect Pharmaceutical Mixed Fund have returns of 129.97% and 117.54% respectively [2] - Funds focusing on innovative pharmaceuticals have been particularly successful, with several funds achieving returns over 90% in related sectors [2] Fund Management Trends - A significant number of high-performing funds are now implementing purchase limits due to increased investor interest and inflows, with nearly 30 funds announcing restrictions on large subscriptions [4] - Recent fund issuance has also seen a resurgence, with several funds raising over 1 billion yuan, indicating a growing market interest [4] - The trend of increasing fund management activity suggests that equity funds are becoming a key avenue for reallocating household savings [4] Market Outlook - The ongoing supportive policies for the capital market are expected to enhance investor risk appetite, with potential catalysts in technology, high-end manufacturing, and consumer sectors [5] - The release of semi-annual earnings from listed companies is anticipated to improve the effectiveness of investment strategies, particularly in sectors with concentrated catalysts [5]

Core Viewpoint - The 2025 World Artificial Intelligence Conference (WAIC) in Shanghai highlighted the significant role of AI in accelerating drug development and transforming the healthcare ecosystem, with a focus on innovation in the pharmaceutical industry [1][4]. Industry Insights - AI technology is rapidly evolving, enabling faster analysis of vast medical data, predicting drug efficacy, and shortening drug development cycles while reducing costs [1][4]. - The global pharmaceutical landscape is undergoing a transformation, with multinational companies increasingly sourcing innovative drugs from China, driven by supportive domestic policies and steady clinical advancements [1][4]. - The innovative drug sector has shown strong performance, with the Wind Innovation Drug Index rising by 48.51% and the Hong Kong Innovation Drug Index increasing by 104.51% as of July 31, 2025 [3]. Company Performance - The performance of the Noan Selected Value Mixed Fund has been notable, with a net value growth rate of 61.88% over the past six months, significantly outperforming its benchmark of 5.74% [3]. - The fund's strategy has focused on the undervaluation of the pharmaceutical sector, with a balanced investment approach in both Hong Kong and A-share markets [3][4]. - The establishment of the "Technology Group" by Noan Fund in 2020 reflects a proactive approach to building a diverse product matrix in the technology investment space [4]. Technological Advancements - Modern surgical robots are enhancing surgical precision by analyzing real-time data and providing feedback, which reduces risks and improves success rates [2]. - The rise of remote surgery, facilitated by 5G/6G networks, allows surgeons to operate on patients from thousands of kilometers away, improving access to healthcare in remote areas [2].

Group 1 - The innovative drug sector has seen significant performance this year, with multiple funds achieving net value doubling, and the top performer nearing a 140% return, leading to a suspension of new subscriptions [1][3] - As of July 28, the top-performing fund, Huatai-PineBridge Hong Kong Advantage Selected Mixed Fund (QDII), reported a return of 139.12%, attracting substantial inflows [3][4] - Other notable funds include Changcheng Pharmaceutical Industry Selected Mixed Fund with a return of 129.35% and Zhongyin Hong Kong Stock Connect Pharmaceutical Mixed Fund at 119.64% [4] Group 2 - The innovative drug sector remains a focal point for market attention, with strong inflows into various innovative drug-themed ETFs, indicating robust investor interest [7] - On July 30, Huabao Hong Kong Stock Connect Innovative Drug ETF surged nearly 9%, prompting the fund company to issue a risk alert due to high premium rates [7][9] - The trading volume for Huabao Hong Kong Stock Connect Innovative Drug ETF reached 2.502 billion yuan, with a turnover rate of 568.61%, reflecting intense market activity [9] Group 3 - Fund managers highlight the ongoing support from policies, continuous R&D advancements, and accelerated internationalization as key factors for the innovative drug sector's positive outlook [9][10] - Upcoming clinical data and academic conferences, such as the European Society of Cardiology Congress and the European Society for Medical Oncology Congress, are expected to catalyze further developments in the sector [9] - The internationalization of China's innovative drug industry is gaining momentum, with numerous product collaboration agreements with multinational companies, enhancing investor confidence [10]

Group 1 - The performance of actively managed equity funds has significantly improved this year, with over 90% achieving positive returns and a notable emergence of "doubling funds" [1][2] - As of July 28, the average return of actively managed equity funds is 13.74%, with nearly 400 funds exceeding 30% returns and around 60 funds surpassing 60% [1] - Several funds have reported returns exceeding 100%, including the Changcheng Medical Industry Selected Mixed Fund at 120.89% and the Huatai-PB Hang Seng Innovation Drug ETF [1][2] Group 2 - Funds heavily invested in the innovative drug sector have shown strong performance, with the sector continuing to rise as of July 29, indicating potential for more "doubling funds" [2] - Other sectors such as technology and new consumption are also performing well, with funds like the GF Growth Leading Mixed Fund achieving a return of 90.5% [2] - The risk appetite of private equity and financing funds has played a crucial role in driving market uptrends since June 23, contributing to a structural market rally [2] Group 3 - The market recovery has sparked enthusiasm among fund companies, with 48 equity funds currently in issuance and 39 more set to launch soon [3] - Public funds have increased their stock positions significantly, with the average allocation for equity mixed funds rising to approximately 85.99% as of July 25, up by 2.05 percentage points from July 18 [3]

近期，科技产业成为市场关注焦点，多领域传来积极信号推动相关板块活跃度提升。AI领域，英伟达 H20对华销售重启、云厂商资本开支增长预期升温，带动AI硬件、CPO等细分赛道走强；人形机器人赛 道受行业大会及技术进展催化，市场关注度持续攀升；半导体板块则因国产替代进程加速，叠加华为等 企业在计算架构上的创新突破，展现出强劲增长动能。与此同时，创新药板块凭借"大额对外授权"等逻 辑演绎，军工板块因技术实力获国际认可，共同构成科技及相关领域的投资热点矩阵。 2025年二季度基金季报已经披露结束，诺安基金科技组多位基金经理基于对产业趋势的深度研判。在创 新药领域，诺安基金科技组的布局尤为引人瞩目。基金经理唐晨管理的诺安精选价值混合基金，战略性 布局A股和H股创新药板块，精准捕捉行业"时代大单品"的核心驱动逻辑。唐晨在二季报中强调，其核 心选股策略是"寻找与时代相契合的超级大单品"，敢于在市场调整期识别被低估的"期权价值"机会。这 一策略成效斐然，截至2025年6月30日，诺安精选价值混合A2025年以来净值增长率为61.88%，同期比 较基准为5.74%，(数据来源，诺安基金，托管行已复核)据银河证券2025年7月20 ...

风险提示：市场有风险，投资须谨慎。本观点仅代表当时观点，今后可能发生改变，仅供参考，不构成 投资建议或保证，亦不作为任何法律文件。现任基金经理可能会根据市场情况在符合《基金合同》等法 律文件约定的前提下调整投资策略和资产配置比例。投资者投资于本公司管理的基金时，应认真阅读 《基金合同》、《托管协议》、《招募说明书》、《风险说明书》基金产品资料概要等文件及相关公 告，如实填写或更新个人信息并核对自身的风险承受能力，选择与自己风险识别能力和风险承受能力相 匹配的基金产品。投资者需要了解基金投资存在可能导致本金亏损的情形。基金管理人承诺以诚实信 用、勤勉尽责的原则管理和运用基金资产，但不保证基金一定盈利，也不保证最低收益。基金管理人管 理的其他基金的业绩不代表本基金业绩表现。基金的过往业绩及其净值高低并不预示其未来业绩表现。 基金管理人提醒投资者基金投资的"买者自负"原则，在做出投资决策后，基金运营状况与基金净值变化 引致的投资风险，由投资者自行负担。我国基金运作时间较短，不能反映股市发展的所有阶段。 诺安精选价值混合型证券投资基金风险等级为【R3】，适合风险识别、评估、承受能力被评定为 【C3】及以上投资者。不同 ...